NCT02287129View on ClinicalTrials.gov

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 5, 2014

Primary Completion Date

August 7, 2020

Study Completion Date

August 7, 2020

Conditions
Adenocarcinoma of the Esophagogastric Junction
Interventions
DRUG

Oxaliplatin

130 mg/m2

DRUG

Epirubicin

50 mg/m2

DRUG

Capecitabine

625 mg/m2

DRUG

5-FU

200 mg/m2

DRUG

Carboplatin

2 mg/ml min

DRUG

Paclitaxel

50 mg/m2

RADIATION

radiation

total dosage 41,4 Gy

PROCEDURE

Biopsy

translational analysis

Trial Locations (1)

81675

2nd department of the Medical Clinic of the Technical University Munich, Munich

All Listed Sponsors
lead

Technical University of Munich

OTHER

NCT02287129 - Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction | Biotech Hunter | Biotech Hunter